CAPS Medical
Selective Minimally Invasive Treatment of Solid Tumors
Company Overview
Snapshot
Founded in December 2018 by Ilan Uchitel, CAPS Medical operates with 11–50 employees. The company has raised $8.3 million across two funding rounds from four investors. In October 2025, CAPS Medical received FDA Breakthrough Device Designation for its PlasmaSure™ System, marking a significant milestone in its development.
Business overview
CAPS Medical is a medical device company developing and commercializing its NTAP System, which utilizes non-thermal atmospheric plasma (NTAP) for the selective treatment of solid tumors. This minimally invasive technology aims to precisely destroy cancerous cells while preserving healthy tissue. The company's initial clinical studies have focused on non-muscle invasive bladder cancer (NMIBC), with demonstrated feasibility for expansion to other cancers including those in the lungs, esophagus, stomach, and GI tract. CAPS Medical operates within the Health Tech & Life Sciences sector, specifically targeting medical treatment and therapeutics for healthcare providers.
Strategic signal
In October 2025, CAPS Medical secured FDA Breakthrough Device Designation for its PlasmaSure™ System, designed for non-muscle invasive bladder cancer treatment. This designation accelerates the development and regulatory review process, signaling strong validation of the technology's potential to transform tumor ablation into a simpler, in-office procedure. For investors, this indicates significant progress towards U.S. market entry and reduced regulatory risk, positioning the company for accelerated growth and commercialization.
Log in to access full profile ›Company Intelligence Q&A
- What is CAPS Medical's core technology?
- CAPS Medical develops the NTAP System, which uses non-thermal atmospheric plasma (NTAP) for selective tumor ablation. This technology is designed to precisely destroy cancerous cells while preserving healthy tissue.
- When was CAPS Medical founded and by whom?
- CAPS Medical was founded in December 2018 by Ilan Uchitel.
- What significant regulatory milestone did CAPS Medical achieve recently?
- In October 2025, CAPS Medical received FDA Breakthrough Device Designation for its PlasmaSure™ System, which is aimed at treating non-muscle invasive bladder cancer (NMIBC).
- Which investors participated in CAPS Medical's funding rounds?
- CAPS Medical has received funding from investors including Chasing Value Asset Management.
- What is the primary focus of CAPS Medical's clinical studies?
- CAPS Medical has completed its first clinical study focusing on non-muscle invasive bladder cancer (NMIBC) and is preparing for pivotal trials. The company is also exploring the technology's application for other cancers such as those in the lungs, esophagus, stomach, and GI tract.